News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
YZYBIO-B (02496.HK) M701 NDA for Malignant Ascites Accepted
YZYBIO-B (02496.HK) announced that the New Drug Application (NDA) for its self-developed bispecific antibody M701, indicated for malignant ascites caused by advanced epithelial mal...
Reset
Send
The window will close in 5 seconds
YZYBIO-B (02496.HK) M701 NDA for Malignant Ascites Accepted
Close
Recommend
3
Positive
1
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

YZYBIO-B (02496.HK)  0.000 (0.000%)   announced that the New Drug Application (NDA) for its self-developed bispecific antibody M701, indicated for malignant ascites caused by advanced epithelial malignancies, has been formally accepted by the National Medical Products Administration.

M701 is undergoing multiple clinical trials in China at different stages for malignant ascites and malignant pleural effusion. These include a pivotal Phase III clinical trial for malignant ascites caused by epithelial solid tumors, for which the NDA has been formally accepted by the National Medical Products Administration, as well as a Phase II clinical trial for malignant pleural effusion caused by non-small cell lung cancer, which has completed patient enrollment. (ha/da)(HK stocks quote is delayed for at least 15 mins.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.